299 related articles for article (PubMed ID: 25077548)
1. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
Gross P; Six I; Kamel S; Massy ZA
Circ J; 2014; 78(10):2339-46. PubMed ID: 25077548
[TBL] [Abstract][Full Text] [Related]
2. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
3. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
5. Vascular Calcification: An Important Understanding in Nephrology.
Zununi Vahed S; Mostafavi S; Hosseiniyan Khatibi SM; Shoja MM; Ardalan M
Vasc Health Risk Manag; 2020; 16():167-180. PubMed ID: 32494148
[TBL] [Abstract][Full Text] [Related]
6. Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.
Latif F; Khalid MM; Khan F; Omar Z; Ali FA
J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):410-5. PubMed ID: 23392553
[TBL] [Abstract][Full Text] [Related]
7. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
Gao Y; Wang G; Li Y; Lv C; Wang Z
J Nephrol; 2019 Apr; 32(2):265-272. PubMed ID: 30588573
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress contributes to vascular calcification in patients with chronic kidney disease.
Huang M; Zheng L; Xu H; Tang D; Lin L; Zhang J; Li C; Wang W; Yuan Q; Tao L; Ye Z
J Mol Cell Cardiol; 2020 Jan; 138():256-268. PubMed ID: 31866376
[TBL] [Abstract][Full Text] [Related]
10. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
11. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
12. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
[TBL] [Abstract][Full Text] [Related]
13. Hyperphosphatemia. The hidden killer in chronic kidney disease.
Askar AM
Saudi Med J; 2015 Jan; 36(1):13-9. PubMed ID: 25629999
[TBL] [Abstract][Full Text] [Related]
14. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
Spasovski G
Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
[TBL] [Abstract][Full Text] [Related]
16. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
Dhillon-Jhattu S; Sprague SM
Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
[TBL] [Abstract][Full Text] [Related]
17. Vascular calcification in chronic kidney disease: a review.
de Oliveira RB; Okazaki H; Stinghen AE; Drüeke TB; Massy ZA; Jorgetti V
J Bras Nefrol; 2013; 35(2):147-61. PubMed ID: 23812573
[TBL] [Abstract][Full Text] [Related]
18. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.
Six I; Maizel J; Barreto FC; Rangrez AY; Dupont S; Slama M; Tribouilloy C; Choukroun G; Mazière JC; Bode-Boeger S; Kielstein JT; Drüeke TB; Massy ZA
Cardiovasc Res; 2012 Oct; 96(1):130-9. PubMed ID: 22822101
[TBL] [Abstract][Full Text] [Related]
19. Gustatory Function and the Uremic Toxin, Phosphate, Are Modulators of the Risk of Vascular Calcification among Patients with Chronic Kidney Disease: A Pilot Study.
Chen SI; Chiang CL; Chao CT; Chiang CK; Huang JW
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32630499
[TBL] [Abstract][Full Text] [Related]
20. Vascular calcification in CKD: New insights into its mechanisms.
Ding N; Lv Y; Su H; Wang Z; Kong X; Zhen J; Lv Z; Wang R
J Cell Physiol; 2023 Jun; 238(6):1160-1182. PubMed ID: 37269534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
